{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T08:49:51Z","timestamp":1773910191832,"version":"3.50.1"},"reference-count":86,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2021,1,16]],"date-time":"2021-01-16T00:00:00Z","timestamp":1610755200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomolecules"],"abstract":"<jats:p>Over the years, a wide variety of therapeutic antibodies has been successfully introduced in the auto-immunology clinic, and many more are on the way. Many of these treatments address either a pathogenic circulating molecule or a cell-bound molecule. Whereas addressing the former target results in neutralization of the soluble factor and binding to the latter target either inhibits cellular function or induces selective cell death. If this targeted molecule or cell is part of the immune system, this therapy evokes a state of immunodeficiency with infections as a possible consequence. Therefore, immune monitoring is needed to prevent such adverse side effects of immunotherapy. In this paper, different immunotherapies used in Sj\u00f6gren\u2019s syndrome, as well as different approaches to monitoring the immune system, are discussed.<\/jats:p>","DOI":"10.3390\/biom11010116","type":"journal-article","created":{"date-parts":[[2021,1,18]],"date-time":"2021-01-18T05:17:34Z","timestamp":1610947054000},"page":"116","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Immune Monitoring upon Treatment with Biologics in Sj\u00f6gren\u2019s Syndrome: The What, Where, When, and How"],"prefix":"10.3390","volume":"11","author":[{"given":"Joyce J.B.C.","family":"van Beers","sequence":"first","affiliation":[{"name":"Central Diagnostic Laboratory Maastricht University Medical Center, Laboratory Specialist in Medical Immunology and Clinical Chemistry, 6202 AZ Maastricht, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4007-6985","authenticated-orcid":false,"given":"Jan G.M.C.","family":"Damoiseaux","sequence":"additional","affiliation":[{"name":"Central Diagnostic Laboratory Maastricht University Medical Center, Laboratory Specialist in Medical Immunology, 6202 AZ Maastricht, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,1,16]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"191","DOI":"10.7150\/ijms.17718","article-title":"Reviewing primary Sj\u00f6gren\u2019s syndrome: Beyond the dryness\u2014From pathophysiology to diagnosis and treatment","volume":"14","author":"Both","year":"2017","journal-title":"Int. J. Med. Sci."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1136\/annrheumdis-2016-210571","article-title":"2016 American College of Rheumatology\/European League against Rheumatism classification criteria for primary Sj\u00f6gren\u2019s syndrome: A consensus and data-driven methodology involving three international patient cohorts","volume":"76","author":"Shiboski","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"ref_3","first-page":"283","article-title":"Ten years of the ESSDAI: Is it fit for purpose?","volume":"126","author":"Arends","year":"2020","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e000022","DOI":"10.1136\/rmdopen-2014-000022","article-title":"EULAR Sj\u00f6gren\u2019s syndrome disease activity index (ESSDAI): A user guide","volume":"1","author":"Seror","year":"2015","journal-title":"RMD Open"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1136\/annrheumdis-2013-204615","article-title":"Validation of EULAR primary Sj\u00f6gren\u2019s syndrome disease activity (ESSDAI) and patient indexes (ESSPRI)","volume":"74","author":"Seror","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1136\/ard.2010.143743","article-title":"EULAR Sj\u00f6gren\u2019s syndrome patient reported index (ESSPRI): Development of a consensus patient index for primary Sj\u00f6gren\u2019s syndrome","volume":"70","author":"Seror","year":"2011","journal-title":"Ann. Rheum. Dis."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jaut.2012.05.014","article-title":"B cells in Sj\u00f6gren\u2019s syndrome: From pathophysiology to diagnosis and treatment","volume":"39","author":"Cornec","year":"2012","journal-title":"J. Autoimmun."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1002\/art.1780180403","article-title":"Immunologic characterization of the mononuclear cell infiltrates in rheumatoid synovia, in rheumatoid nodules, and in lip biopsies from patients with Sj\u00f6gren\u2019s syndrome","volume":"18","author":"Tannenbaum","year":"1975","journal-title":"Arthritis Rheum."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1056\/NEJMc1804598","article-title":"Primary Sj\u00f6gren\u2019s syndrome","volume":"379","author":"Henkin","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1080\/14728214.2019.1634052","article-title":"Emerging drugs for primary Sj\u00f6gren\u2019s syndrome","volume":"24","author":"Gandolfo","year":"2019","journal-title":"Expert Opin. Emerg. Drugs"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/j.1365-2249.1991.tb05780.x","article-title":"Detection and occurrence of the 60- and 52-kD Ro (SS-A) antigens and of autoantibodies against these proteins","volume":"86","author":"Slobbe","year":"1991","journal-title":"Clin. Exp. Immunol."},{"key":"ref_12","first-page":"315","article-title":"Pathogenesis of primary Sjogren\u2019s syndrome beyond B lymphocytes","volume":"126","author":"Fasano","year":"2020","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1093\/rheumatology\/kez268","article-title":"Epigenetically quantified immune cells in salivary glands of Sj\u00f6gren\u2019s syndrome patients: A novel tool that detects robust correlations of T follicular helper cells with immunopathology","volume":"59","author":"Blokland","year":"2020","journal-title":"Rheumatology"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.3389\/fimmu.2018.01755","article-title":"IL-2 inhibition of Th17 generation rather than induction of treg cells is impaired in primary Sj\u00f6gren\u2019s syndrome patients","volume":"9","author":"Luo","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/cei.13077","article-title":"Activation of plasmacytoid dendritic cells by apoptotic particles\u2014Mechanism for the loss of immunological tolerance in Sj\u00f6gren\u2019s syndrome","volume":"191","author":"Ainola","year":"2017","journal-title":"Clin. Exp. Immunol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.3389\/fimmu.2018.02594","article-title":"CCL22-producing resident macrophages enhance T cell response in Sj\u00f6gren\u2019s syndrome","volume":"9","author":"Ushio","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.rdc.2016.03.010","article-title":"New treatment guidelines for Sj\u00f6gren\u2019s disease","volume":"42","author":"Vivino","year":"2016","journal-title":"Rheum. Dis. Clin. N. Am."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/annrheumdis-2019-216114","article-title":"EULAR recommendations for the management of Sj\u00f6gren\u2019s syndrome with topical and systemic therapies","volume":"79","author":"Bombardieri","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"ref_19","first-page":"10","article-title":"One year in review 2020: Comorbidities, diagnosis and treatment of primary Sjogren\u2019s syndrome","volume":"126","author":"Manfre","year":"2020","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.autrev.2018.12.008","article-title":"The pipeline of targeted therapies under clinical development for primary Sj\u00f6gren\u2019s syndrome: A systematic review of trials","volume":"18","author":"Felten","year":"2019","journal-title":"Autoimmun. Rev."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"713","DOI":"10.2217\/imt-2017-0178","article-title":"Consequences of B-cell-depleting therapy: Hypogammaglobulinemia and impaired B-cell reconstitution","volume":"10","author":"Sacco","year":"2018","journal-title":"Immunotherapy"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"163","DOI":"10.3389\/fonc.2018.00163","article-title":"Past, present, and future of rituximab\u2014The world\u2019s first oncology monoclonal antibody therapy","volume":"8","author":"Pierpont","year":"2018","journal-title":"Front. Oncol."},{"key":"ref_23","first-page":"233","article-title":"Treatment of primary Sj\u00f6gren syndrome with rituximab","volume":"160","author":"Mariette","year":"2014","journal-title":"Ann. Intern. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1002\/art.40093","article-title":"Randomized controlled trial of rituximab and cost-effectiveness analysis in treating fatigue and oral dryness in primary Sj\u00f6gren\u2019s syndrome","volume":"69","author":"Bowman","year":"2017","journal-title":"Arthritis Rheumatol."},{"key":"ref_25","first-page":"167","article-title":"Present and novel biologic drugs in primary Sjogren\u2019s syndrome","volume":"118","author":"Fasano","year":"2019","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"\u00c1lvarez-Rivas, N., Sang-Park, H., Del Campo, P.D., Fern\u00e1ndez-Castro, M., Corominas, H., Andreu, J.L., and Navarro-Comp\u00e1n, V. (2020). Efficacy of belimumab in primary Sj\u00f6gren\u2019s syndrome: A systematic review. Reumatol. Clin.","DOI":"10.1016\/j.reuma.2020.03.003"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1136\/annrheumdis-2013-203991","article-title":"Efficacy and safety of belimumab in primary Sj\u00f6gren\u2019s syndrome: Results of the BELISS open-label phase II study","volume":"74","author":"Mariette","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1084\/jem.20032000","article-title":"TACI and BAFF-R mediate isotype switching in B cells","volume":"201","author":"Castigli","year":"2005","journal-title":"J. Exp. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1136\/annrheumdis-2018-214720","article-title":"Treatment of primary Sj\u00f6gren\u2019s syndrome with ianalumab (VAY736) targeting B cells by BAFF receptor blockade coupled with enhanced, antibody-dependent cellular cytotoxicity","volume":"78","author":"Posch","year":"2019","journal-title":"Ann. Rheum. Dis."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"R129","DOI":"10.1186\/ar2018","article-title":"Epratuzumab (humanised anti-CD22 antibody) in primary Sj\u00f6gren\u2019s syndrome: An open-label phase I\/II study","volume":"8","author":"Steinfeld","year":"2006","journal-title":"Arthritis Res. Ther."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1002\/art.40513","article-title":"Clinical efficacy and safety of baminercept, a lymphotoxin \u03b2 receptor fusion protein, in primary Sj\u00f6gren\u2019s syndrome","volume":"70","author":"Baer","year":"2018","journal-title":"Arthritis Rheumatol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/j.immuni.2016.04.017","article-title":"Co-stimulatory and co-inhibitory pathways in autoimmunity","volume":"44","author":"Zhang","year":"2016","journal-title":"Immunity"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"102364","DOI":"10.1016\/j.jaut.2019.102364","article-title":"Sj\u00f6gren\u2019s syndrome: Old and new therapeutic targets","volume":"110","author":"Kelly","year":"2020","journal-title":"J. Autoimmun."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.immuni.2016.04.020","article-title":"CD28 costimulation: From mechanism to therapy","volume":"44","author":"Esensten","year":"2016","journal-title":"Immunity"},{"key":"ref_35","first-page":"222","article-title":"Blocking T cell co-stimulation in primary Sj\u00f6gren\u2019s syndrome: Rationale, clinical efficacy and modulation of peripheral and salivary gland biomarkers","volume":"126","author":"Pontarini","year":"2020","journal-title":"Clin. Exp. Rheumatol"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"E153","DOI":"10.1016\/S2665-9913(19)30160-2","article-title":"Abatacept treatment for patients with early active primary Sj\u00f6gren\u2019s syndrome: A single-centre, randomised, double-blind, placebo-controlled, phase 3 trial (ASAP-III study)","volume":"2","author":"Mossel","year":"2020","journal-title":"Lancet Rheumatol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1002\/art.40165","article-title":"Attenuation of follicular helper T cell-dependent B Cell hyperactivity by abatacept treatment in primary Sj\u00f6gren\u2019s syndrome","volume":"69","author":"Verstappen","year":"2017","journal-title":"Arthritis Rheumatol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"101485","DOI":"10.1016\/j.berh.2020.101485","article-title":"Targeted therapies in systemic sclerosis, myositis, antiphospholipid syndrome, and Sj\u00f6gren\u2019s syndrome","volume":"34","author":"Hoogen","year":"2020","journal-title":"Best Pract. Res. Clin. Rheumatol."},{"key":"ref_39","unstructured":"(2021, January 15). Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02843659."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.imlet.2006.02.007","article-title":"CD28 and ICOS: Similar or separate costimulators of T cells?","volume":"105","author":"Oosterwegel","year":"2006","journal-title":"Immunol. Lett."},{"key":"ref_41","first-page":"2417","article-title":"Phase 2a study of MEDI5872 (AMG557), a fully human anti-ICOS ligand monoclonal antibody in patients with primary Sj\u00f6gren\u2019s syndrome","volume":"71","author":"Bombardieri","year":"2019","journal-title":"Arthritis Rheumatol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/j.autrev.2018.04.002","article-title":"Nature versus nurture in the spectrum of rheumatic diseases: Classification of spondyloarthritis as autoimmune or autoinflammatory","volume":"17","author":"Generali","year":"2018","journal-title":"Autoimmun. Rev."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/sji.12121","article-title":"Upregulation of membrane-bound CD40L on CD4+T cells in women with primary Sj\u00f6gren\u2019s syndrome","volume":"79","author":"Belkhir","year":"2013","journal-title":"Scand. J. Immunol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"E142","DOI":"10.1016\/S2665-9913(19)30135-3","article-title":"Assessment of the anti-CD40 antibody iscalimab in patients with primary Sj\u00f6gren\u2019s syndrome: A multicentre, randomised, double-blind, placebo-controlled, proof-of-concept study","volume":"2","author":"Fisher","year":"2020","journal-title":"Lancet Rheumatol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1089\/jop.2018.0047","article-title":"Suppression of Th1-mediated keratoconjunctivitis sicca by lifitegrast","volume":"34","author":"Yu","year":"2018","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s00018-015-2062-4","article-title":"The common \u03b3-chain cytokine receptor: Tricks-and-treats for T cells","volume":"73","author":"Waickman","year":"2016","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"109704","DOI":"10.1016\/j.biopha.2019.109704","article-title":"Molecular mechanisms and clinical application of Iguratimod: A review","volume":"122","author":"Jiang","year":"2020","journal-title":"Biomed. Pharmacother."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1007\/s10792-020-01490-6","article-title":"The efficacy and mechanism for action of iguratimod in primary Sj\u00f6gren\u2019s syndrome patients","volume":"40","author":"Jiang","year":"2020","journal-title":"Int. Ophthalmol."},{"key":"ref_49","first-page":"1","article-title":"Efficacy and safety of iguratimod on patients with primary Sj\u00f6gren\u2019s syndrome: A randomized, placebo-controlled clinical trial","volume":"2020","author":"Shao","year":"2020","journal-title":"Scand. J. Rheumatol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1111\/j.1601-0825.2009.01582.x","article-title":"Cytokines in Sj\u00f6gren\u2019s syndrome","volume":"15","author":"Roescher","year":"2009","journal-title":"Oral Dis."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1002\/art.20299","article-title":"Etanercept in Sj\u00f6gren\u2019s syndrome: A twelve-week randomized, double-blind, placebo-controlled pilot clinical trial","volume":"50","author":"Sankar","year":"2004","journal-title":"Arthritis Rheum."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1002\/art.20146","article-title":"Inefficacy of infliximab in primary Sj\u00f6gren\u2019s syndrome: Results of the randomized, controlled trial of remicade in primary Sj\u00f6gren\u2019s syndrome (TRIPSS)","volume":"50","author":"Mariette","year":"2004","journal-title":"Arthritis Rheum."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Norheim, K.B., Harboe, E., G\u00f8ransson, L.G., and Omdal, R. (2012). Interleukin-1 inhibition and fatigue in primary Sj\u00f6gren\u2019s syndrome\u2014A double blind, randomised clinical trial. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0030123"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"294","DOI":"10.3109\/14397595.2013.861333","article-title":"Neuromyelitis optica spectrum disorder complicated with Sj\u00f6gren syndrome successfully treated with tocilizumab: A case report","volume":"26","author":"Komai","year":"2013","journal-title":"Mod. Rheumatol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"e16285","DOI":"10.1097\/MD.0000000000016285","article-title":"Refractory Sj\u00f6gren\u2019s syndrome myelopathy successfully treated with subcutaneous tocilizumab","volume":"98","author":"Ishikawa","year":"2019","journal-title":"Medicine"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/0-387-27545-2_16","article-title":"Immune monitoring","volume":"123","author":"Mosca","year":"2005","journal-title":"Cancer Treat. Res."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1002\/art.30236","article-title":"B cell reconstitution and T helper cell balance after rituximab treatment of active primary Sj\u00f6gren\u2019s syndrome: A double-blind, placebo-controlled study","volume":"63","author":"Abdulahad","year":"2011","journal-title":"Arthritis Rheum."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Gatti, A., Buccisano, F., Scupoli, M.T., and Brando, B. (2020). The ISCCA flow protocol for the monitoring of anti-CD20 therapies in autoimmune disorders. Cytometry B Clin. Cytom.","DOI":"10.1002\/cyto.b.21930"},{"key":"ref_59","first-page":"1","article-title":"B cell repopulation kinetics after rituximab treatment in ANCA-associated vasculitides compared to rheumatoid arthritis, and connective tissue diseases: A longitudinal observational study on 120 patients","volume":"19","author":"Thiel","year":"2017","journal-title":"Arthritis Res."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/art.10764","article-title":"The relationship of Fc\u03b3RIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus","volume":"48","author":"Anolik","year":"2003","journal-title":"Arthritis Rheum."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1007\/s12016-007-8015-4","article-title":"B-cell depletion and repopulation in autoimmune diseases","volume":"34","author":"Pers","year":"2007","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.3389\/fimmu.2019.03069","article-title":"Neutralizing anti-rituximab antibodies and relapse in membranous nephropathy treated with rituximab","volume":"10","author":"Andreani","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1002\/cyto.b.21747","article-title":"Adult bone marrow three-dimensional phenotypic landscape of B-cell differentiation","volume":"96","author":"Carrion","year":"2019","journal-title":"Cytom. Part B Clin. Cytom."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1136\/ard.2008.096172","article-title":"Is the blood B-cell subset profile diagnostic for Sj\u00f6gren syndrome?","volume":"68","author":"Binard","year":"2008","journal-title":"Ann. Rheum. Dis."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1002\/art.22019","article-title":"Regeneration of B cell subsets after transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis","volume":"54","author":"Roll","year":"2006","journal-title":"Arthritis Rheum."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1002\/art.21617","article-title":"Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis","volume":"54","author":"Leandro","year":"2006","journal-title":"Arthritis Rheum."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.ebiom.2018.12.035","article-title":"B cell alterations during BAFF inhibition with belimumab in SLE","volume":"40","author":"Parodis","year":"2019","journal-title":"EBioMedicine"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.3389\/fimmu.2018.01637","article-title":"T follicular helper cells in autoimmune disorders","volume":"9","author":"Gensous","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_69","first-page":"1","article-title":"T follicular helper cell subsets: A potential key player in autoimmunity","volume":"2020","author":"Kurata","year":"2020","journal-title":"Immunol. Med."},{"key":"ref_70","first-page":"177","article-title":"Analysis of tear inflammatory mediators: A comparison between the microarray and Luminex methods","volume":"22","author":"Dionne","year":"2016","journal-title":"Mol. Vis."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"7595","DOI":"10.12659\/MSM.912010","article-title":"Tear Luminex analysis in dry eye patients","volume":"24","author":"Zhao","year":"2018","journal-title":"Med. Sci. Monit."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"7319","DOI":"10.1038\/s41598-019-43714-5","article-title":"Elevated cytokine levels in tears and saliva of patients with primary Sj\u00f6gren\u2019s syndrome correlate with clinical ocular and oral manifestations","volume":"9","author":"Chen","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/nrrheum.2012.66","article-title":"New tools for classification and monitoring of autoimmune diseases","volume":"8","author":"Maecker","year":"2012","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"6813","DOI":"10.1021\/ac901049w","article-title":"Mass cytometry: Technique for real time single cell multitarget immunoassay based on inductively coupled plasma time-of-flight mass spectrometry","volume":"81","author":"Bandura","year":"2009","journal-title":"Anal. Chem."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/s41584-019-0338-z","article-title":"Immune monitoring using mass cytometry and related high-dimensional imaging approaches","volume":"16","author":"Hartmann","year":"2019","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.celrep.2019.06.049","article-title":"Comprehensive immune monitoring of clinical trials to advance human immunotherapy","volume":"28","author":"Hartmann","year":"2019","journal-title":"Cell Rep."},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Marco, H., Smith, R.M., Jones, R.B., Guerry, M.-J., Catapano, F., Burns, S., Chaudhry, A.N., Smith, K.G.C., and Jayne, D.R.W. (2014). The effect of rituximab therapy on immunoglobulin levels in patients with multisystem autoimmune disease. BMC Musculoskelet. Disord., 15.","DOI":"10.1186\/1471-2474-15-178"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1182\/blood.V83.2.435.435","article-title":"Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20","volume":"83","author":"Reff","year":"1994","journal-title":"Blood"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1111\/ajt.12220","article-title":"A single dose of rituximab does not deplete B Cells in secondary lymphoid organs but alters phenotype and function","volume":"13","author":"Kamburova","year":"2013","journal-title":"Am. J. Transplant."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1053\/j.seminhematol.2010.01.002","article-title":"Rituximab-associated infections","volume":"47","year":"2010","journal-title":"Semin. Hematol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s00277-010-0962-9","article-title":"Hepatitis B reactivation induced by Rituximab maintenance therapy for lymphoma","volume":"90","author":"Cho","year":"2010","journal-title":"Ann. Hematol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1136\/ard.2007.077461","article-title":"Vaccination against influenza in patients with rheumatoid arthritis: The effect of rituximab on the humoral response","volume":"67","author":"Oren","year":"2008","journal-title":"Ann. Rheum. Dis."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"R111","DOI":"10.1186\/ar3047","article-title":"Vaccination response to protein and carbohydrate antigens in patients with rheumatoid arthritis after rituximab treatment","volume":"12","author":"Rehnberg","year":"2010","journal-title":"Arthritis Res. Ther."},{"key":"ref_84","first-page":"75","article-title":"Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab","volume":"62","author":"Holvast","year":"2009","journal-title":"Arthritis Rheum."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"246","DOI":"10.3389\/fimmu.2019.00246","article-title":"The EuroFlow PID orientation tube for flow cytometric diagnostic screening of primary immunodeficiencies of the lymphoid system","volume":"10","author":"Kalina","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.3389\/fimmu.2019.01271","article-title":"EuroFlow-based flowcytometric diagnostic screening and classification of primary immunodeficiencies of the lymphoid system","volume":"10","author":"Kalina","year":"2019","journal-title":"Front. Immunol."}],"container-title":["Biomolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2218-273X\/11\/1\/116\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T05:12:03Z","timestamp":1760159523000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2218-273X\/11\/1\/116"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,16]]},"references-count":86,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,1]]}},"alternative-id":["biom11010116"],"URL":"https:\/\/doi.org\/10.3390\/biom11010116","relation":{},"ISSN":["2218-273X"],"issn-type":[{"value":"2218-273X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,16]]}}}